|
Bone-Rad Therapeutics, Inc. aims to develop and market radioactive bone cement as an innovative, improved, and cost-effective treatment paradigm in the management of cancer tumors in bone. This patent-pending technology, developed at the University of California, Irvine (UCI) by members of the Bone-Rad Therapeutics team, promises to provide a more focused radiation therapy to tumor-involved regions of bone, resulting in less radiation exposure to surrounding normal tissues, while simultaneously augmenting the strength of the affected region. Administered in a single procedure, radioactive bone cement will also eliminate the 10 hospital visits typically needed for conventional radiation treatment, making it cost-effective while dramatically improving patient care and quality of life. Through UCI, the members of the Bone-Rad Therapeutics team have already been awarded a $760,000 grant from the Department of Defense (DOD) Breast Cancer Research Program for research and development of this technology for treatment of tumors in the spine. The initial product line will consist of Bone-Rad Radioisotope, Bone Cement, Cement Mixer, and Cement Injector System. The latter three items will be packaged together with private-label spine surgery equipment in a kit that will be sold to hospitals and used by treating physicians. The corporation will take the technology through the required testing period and once FDA market approval has been obtained, a decision will be made to license or sell the technology to the most appropriate company, or to manufacture the products.
|
